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Nucleoside hydrolases of the Leishmania genus are vital enzymes for the replication of the
DNA and conserved phylogenetic markers of the parasites. Leishmania donovani nucleo-
side hydrolase (NH36) induced a main CD4+ T cell driven protective response against L.
chagasi infection in mice which is directed against its C-terminal domain. In this study, we
used the three recombinant domains of NH36: N-terminal domain (F1, amino acids 1–103),
central domain (F2 aminoacids 104–198), and C-terminal domain (F3 amino acids 199–314)
in combination with saponin and assayed their immunotherapeutic effect on Balb/c mice
previously infected with L. amazonensis. We identified that the F1 and F3 peptides deter-
mined strong cross-immunotherapeutic effects, reducing the size of footpad lesions to 48
and 64%, and the parasite load in footpads to 82.6 and 81%, respectively. The F3 pep-
tide induced the strongest anti-NH36 antibody response and intradermal response (IDR)
against L. amazonenis and a high secretion of IFN-γ andTNF-α with reduced levels of IL-10.
The F1 vaccine, induced similar increases of IgG2b antibodies and IFN-γ and TNF-α levels,
but no IDR and no reduction of IL-10.The multiparameter flow cytometry analysis was used
to assess the immune response after immunotherapy and disclosed that the degree of the
immunotherapeutic effect is predicted by the frequencies of the CD4+ and CD8+ T cells
producing IL-2 or TNF-α or both. Total frequencies and frequencies of double-cytokine CD4
T cell producers were enhanced by F1 and F3 vaccines. Collectively, our multifunctional
analysis disclosed that immunotherapeutic protection improved as the CD4 responses pro-
gressed from 1+ to 2+, in the case of the F1 and F3 vaccines, and as the CD8 responses
changed qualitatively from 1+ to 3+, mainly in the case of the F1 vaccine, providing new
correlates of immunotherapeutic protection against cutaneous leishmaniasis in mice based
on T-helper TH1 and CD8+ mediated immune responses.
Keywords: visceral leishmaniasis, cutaneous leishmaniasis, diffuse cutaneous leishmaniasis, cross-
immunotherapy, nucleoside hydrolases, recombinant vaccines
INTRODUCTION
Leishmaniasis is a complex of vector-borne protozoan diseases
the etiological agents of which belong to the Leishmania genus.
The global incidence and prevalence of leishmaniasis is increas-
ing. The main clinical syndromes of leishmaniasis are: cutaneous
(CL), diffuse cutaneous (DCL), mucocutaneous (MCL), and vis-
ceral (VL) (1). While CL accounts for approximately 0.7–1.2
million cases per year, which is more than 50% of the new cases
of leishmaniasis (2). Most of the CL cases occur in the Mediter-
ranean (85,555 cases/year), the Americas (66,941 cases/year), and
the Middle East to Central Asia (61,013 cases/year) (2). The
10 countries with the highest estimated number of cases are:
Afghanistan,Algeria, Colombia, Brazil, Iran, Syria, Ethiopia, North
Sudan, Costa Rica, and Peru and together they account for 70–75%
of the estimated global incidence of CL (2). The disease causes skin
ulcers at the site of the sand-fly bite, usually on exposed parts of the
body, such as the face, neck, arms, and legs and develops an active
T cell mediated immune response that plays a pivotal role in the
processes in the cure or in the aggravation of the disease (3). VL, on
the other hand, has approximately 0.2–0.4 million new cases per
year (2) and is the most severe clinical syndrome of leishmania-
sis characterized by hepato-splenomegaly, malaise, cachexia, fever,
hypergammaglobulinemia, anemia, and the progressive suppres-
sion of the T cell mediated immune response. If left untreated,
the disease has a high mortality rate mainly due to immunosup-
pression and secondary infections. Indeed, anergy to leishmanial
antigens and negative skin tests have been reported in cases of
VL caused by Leishmania donovani and L. infantum/chagasi (4–6),
www.frontiersin.org June 2014 | Volume 5 | Article 273 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nico et al. Nucleoside hydrolase domains in cross-therapy
and DCL caused by L. amazonensis (7) while a strong TH1 pro-
inflammatory response has been detected in cases of CL (8) and
MCL caused by L. braziliensis (9).
Since the chemotherapy of leishmaniasis is highly toxic and the
few available therapeutic drugs are only partially effective (10, 11),
due to an increase in the resistance of parasites to antibiotics, a
protective vaccine would be important not only for prophylaxis
but also for the immunotherapy of the disease. The success of
immunotherapy in the control of human CL leishmaniasis with
the use of crude parasite vaccines combined to BCG has been
reported since the 80s (12–14). Furthermore, immunochemother-
apy against human CL leishmaniasis has been reported to reduce
the time of chemotherapy needed to cure this disease in humans,
thus decreasing its toxicity (15).
Since the epidemics of VL and CL are spreading on a world-
wide scale, even overlapping in some areas, and no human vaccine
is available yet, the development of a bivalent vaccine for the con-
trol of tegumentary and VL leishmaniasis is highly recommended.
Consequently, we believe that the search for cross-protective anti-
gens is mandatory. Recently, we developed the first licensed second
generation vaccine against canine VL leishmaniasis (Leishmune®),
which contains the fucose–mannose ligand (FML) antigen of L.
donovani in formulation with saponin (16–19), is a transmis-
sion blocking vaccine (18, 19) and has already determined a
reduction in the incidence of the human and canine disease in
Brazilian endemic areas (20). Prophylactic vaccination of dogs
with Leishmune® promoted increases in the production of NO,
IgG2 antibodies against FML and L. chagasi, intradermal reac-
tions and proportions of CD8+ lymphocytes, which secrete more
IFN-γ than IL-4 (21, 22) expressing a selective pro-inflammatory
pattern (IFN-γ/NO) (23). The early and persistent activation
of neutrophils and monocytes have also been described (23).
This increase in proportions of CD8+ T cells is expected for
the QS21 saponin adjuvant of Leishmune® (24) and this was
also described in the Leishmune® immunotherapy assays against
naturally (25) and experimentally acquired canine VL leishmani-
asis (26). Furthermore, the sustained or increased proportions
of CD4+ and CD21-B lymphocytes (25, 26) and the reduced
CD4+/CD25+ T cell counts (27) have also been described in
Leishmune® vaccinated dogs.
Leishmune® canine immunotherapy, on the other hand,
reduced the number of deaths and the clinical and parasitolog-
ical signs of canine VL and, when used for immunochemotherapy
with allopurinol, amphotericin, and enrofloxacin, promoted the
sterile cure (28).
QS21 and deacylated saponins of Quillaja saponaria are the
adjuvants of the Leishmune® vaccine (29). The QS21 Stimu-
lon 1 saponin (Agenus) is also the adjuvant currently being
studied in 17 human clinical programs, including four Phase 3
anti-Malaria assays, by GlaxoSmithKline. The anti-Malaria vac-
cine, called the RTS,S or Mosquirix, indeed contains the P. fal-
ciparum cir-cumsporozoite (CS) protein central tandem repeat
and carboxy-terminal regions fused to the amino-terminus of
the S antigen of hepatitis B virus (HBsAg) (30) and the AS01
adjuvant, which is composed of QS21 Stimulon in combination
with monophosphoryl Lipid A (31). The RTS,S/AS01 vaccine
co-administered with EPI vaccines provided modest protection
against both clinical and severe malaria in young infants (32).
The main component of the FML antigen is the nucleoside
hydrolase of L. donovani (NH36), which was the only FML com-
ponent specifically recognized by the sera of patients with human
VL leishmaniasis (33). NH36 is not only a vital enzyme which
cleaves exogenous nucleosides to release pyrimidines or purines
for the DNA synthesis and further replication of the parasite (34,
35), but also a strong antigen (36) present in the early stages of the
parasite infection. It fulfills the requirements for a cross-protective
antigen of a Leishmania vaccine perfectly since it is a strong phylo-
genetic marker Leishmania (37, 38) that shares high identity with
the sequences of the nucleoside hydrolases of L. major (95%) (39),
L. mexicana (93%), L. chagasi (99%), L. infantum (99%), L. trop-
ica (97%), and L. braziliensis (84%) (40). This fact explains why
a vaccine containing NH36, in its native form, reduced the infec-
tion by L. donovani (41) in mice and was characterized as an L.
major exo-antigen (42), and in its recombinant or DNA formula-
tions, protected mice against challenge with L. chagasi, L. mexicana
(43, 44), L. amazonensis (45), and L. major (42), and dogs against
challenge with L. chagasi (46). The DNA-NH36 vaccine induced a
TH1 immune response related to the IFN-γ expression by CD4+
T cells, which led to an 88% prophylactic protection against VL
(43), 65–81% against tegumentary leishmaniasis (42, 43, 45) and
91% immunotherapy againstVL leishmaniasis in the mouse model
(47). Also, higher proportions of CD4+-NH36-specific lympho-
cytes and higher levels of IFN-γ and IL-2 were found in L. chagasi
infected dogs treated with NH36-DNA vaccine (46).
We recently obtained three recombinant fragment proteins rep-
resenting the whole sequence of NH36: amino acids 1–103 (F1,
N-terminal domain), 104–198 (F2, central domain), and 199–314
(F3, C-terminal domain) and used them in a mouse vaccina-
tion against L. chagasi infection in order to map the domain of
NH36, which is the target of the adaptive immunity (48). Pro-
tection against L. chagasi infection in mice was determined by
the C-terminal domain of NH36, which induced a main CD4+
T cell mediated response with a minor contribution of CD8+ T
cells. Protection induced by this C-terminal peptide was superior
to that induced by the whole protein. Vaccination with the C-
terminal determined the increases of antibody titers (IgM, IgG2a,
IgG1, and IgG2b), frequencies of CD4+ T lymphocytes, and lev-
els of IFN-γ in the splenocyte supernatants. The proportions of
CD4+ and CD8+ T lymphocytes generating IFN-γ were higher
than those generating IL-10. Antibodies of Leishmune® vaccinated
dogs showed the most potent reactivity against the epitopes of the
C-terminal domain. The intradermal response (IDR) against L.
donovani antigen and the increase of TNF-α, when compared to
IL-10, expressed by CD4+ lymphocytes were very good correlates
of vaccine induced immunity (48). Important epitopes for mice
(48), human, and dog B cells (49) were also recently demonstrated
in the sequence of the C-terminal domain.
In the search for cross-protection for CL leishmaniasis, we fur-
ther vaccinated mice with the NH36 domains and challenged them
with L. amazonensis (48). Different from the absolute dominance
of the C-terminal domain in immune protection to VL, the most
severe syndrome (1), preliminary results suggest that protection
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against CL by L. amazonensis is mediated by the C-terminal and
the N-terminal domain in similar proportions (48).
In the present work, we studied the immunotherapeutic effect
of NH36 or its peptide components in a formulation with saponin,
on mice infection by L. amazonensis, in order to assess which of
the NH36 domains deserves to be considered as components in a
future cross-therapeutic vaccine for leishmaniasis. We identified
that the N-terminal and C-terminal domains of NH36 induced
strong curative effects which improved, as the CD4 T cell responses
shifted from single- to double-cytokine producers (TNF-α+-IL-
2+), and, in the case of the N-terminal domain vaccine, as the CD8
T cell responses shifted qualitatively from single- to triple-cytokine
producers (TNF-α+-IL-2+-IFN-γ+).
MATERIALS AND METHODS
ETHICAL STATEMENTS
All experiments were reviewed and approved by the Animal Care
and Use Committee of the Instituto de Biofisica Carlos Chagas
Fo.-UFRJ (CAUAP-CONCEA, Brazil, IMPPG-016) and were per-
formed according to the guidelines of the National Institutes of
Health, USA. We made all efforts to minimize animal suffering.
NUCLEOSIDE HYDROLASE-NH36 DOMAINS
The sequence of DNA and amino acids of NH36 is deposited
in the EMBL, GenBank™, and DDJB data bases, access number
AY007193. NH36 is composed of 314 amino acids. The three pep-
tide domains of NH36 codifying, respectively, for the amino acids
1–103 (F1), 104–198 (F2), and 199–314 (F3) were cloned in the
pET28b plasmid and were expressed and chromatographed as
previously described (48). A preliminary molecular model was
obtained through homology modeling using the Modeller9.10
software and the data of the nucleoside hydrolase from L. major
template (RCSB PDB code: 1EZR; Crystal structure of nucleoside
hydrolase of L. major) (50). It is important to note that the model
shown in this investigation is preliminary and not a final, opti-
mized model. The predicted epitopes for MHC class II-IAd and
IEd, haplotype H2d CD4+ T cells, MHC class I Ld-CD8+ T cells,
and B cells were plotted in the C-terminal and N-terminal moieties
of the model (48). Additionally, the analysis of the solvent accessi-
ble surface area of the C-terminal, central, and N-terminal sections
of the tetramer was performed using the PyMol 1.3 software.
IMMUNOTHERAPEUTIC VACCINATION IN LEISHMANIA AMAZONENSIS
INFECTED MICE
Two-month-old Balb/c mice (female) were infected with 105 L.
amazonensis (pH 8 strain) metacyclic promastigotes isolated from
hamsters and maintained in Schneider’s medium in the right hind
footpads (45). The evolution of lesions was monitored weekly
with a caliper apparatus (Mitutoyo) and the swelling of the non-
infected contra-lateral left footpads were subtracted. Six weeks
after infection groups of mice received three doses of 100µg of
NH36, F1, F2, or F3 recombinant proteins and 100µg of SIGMA
saponin (NH36sap, F1sap, F2sap, and F3sap vaccines, respec-
tively), at weekly intervals, in the back by the sc route, while the
control group was treated with saline solution. At 9 weeks after
infection sera were collected for the assay of anti-NH36 antibod-
ies in an ELISA assay and the IDR against L. amazonensis (pH
8) lysate (IDR) was determined in the footpads as described pre-
viously (48). Mice were euthanized with CO2 and their cellular
immune response was assessed by intracellular staining (ICS),
multiparameter cytometry analysis of splenocytes (51, 52), and
by a cytokine-ELISA assay of the splenocytes supernatants. The
total number of parasites in the footpad lesions was determined
after sacrifice by Real Time PCR as previously described (53)
using primers for L. chagasi on DNA isolated from infective pro-
mastigotes of L. amazonensis (pH 8) obtained from hamsters
footpads (48).
ASSESSMENT OF THE CELLULAR IMMUNE RESPONSE
The cellular immune response was assessed using 106 splenocytes
that had been cultured in RPMI for 72 h in vitro at 37°C and 5%
CO2 in the presence or absence of 5µg of NH36. The multipara-
meter analysis (51, 52) was carried out to assess the intracellular
production of IL-2, TNF-α, and IFN-γ cytokines by CD4+ and
CD8+ T lymphocytes. For this evaluation, the cells were treated
with brefeldin (SIGMA) at a final concentration of 10µg/ml, incu-
bated for an additional 4 h, and then stained with rat anti-mouse
CD4FITC (clone GK1.5) and CD8FITC (clone 53–6.7) mono-
clonal antibodies (R&D systems, Inc.) and further stained with
IFN-γAPC, IL-2-PerCP-Cy5.5, and TNF-αPE monoclonal anti-
bodies (BD-Pharmingen) as described before (48). For the ICS
methods, 100,000 lymphocytes were acquired using a BD FACScal-
ibur apparatus. Data were analyzed using the Cell Quest program.
The secretion of cytokines was also evaluated in the supernatants
of splenocytes by an ELISA assay as previously described (48).
STATISTICAL ANALYSIS
The Kruskal Wallis and Mann Whitney non-parametrical tests
were used for comparison of means and the two-tailed Pearson
bivariate analysis for the assessment of the correlation coefficient
(GraphPad Prism 6 for Windows).
RESULTS
To understand more clearly how the peptide domains F1, F2,
and F3 are distributed along the whole of the NH36 molecule,
we obtained the preliminary model of the nucleoside hydrolase-
NH36 by homology to the model of the nucleoside hydrolase of
L. major (Figure 1). Our aim was only to illustrate the mole-
cule. The image of the molecule shows its tetramer composition,
with four identical subunits. The solvent accessible surface area
was computed and this disclosed the distribution of the F1, F2,
and F3 domains (Figure 1A). This tridimensional surface model
of the tetramer revealed that the F3 (C-terminal domain) is the
domain with the largest area of exposed surface (29,507,002 Å)
(Figure 1A). This is followed by the F1 (N-terminal domain) with
an area of 27,132,781 Å. The F2 (central domain) has the small-
est surface area (19,931,451 Å) and is therefore the least exposed
domain (Figure 1A). The detailed monomer (Figure 4B) shows
the F3 as the most exposed peptide, followed by the less exposed
F1, while the F2 fragment (central domain), on the other hand, is
apparently more hidden (Figure 4B). The sequence of F3 includes
three predicted epitopes for CD4+ T cells (Figure 4C) and three
epitopes for antibodies (Figure 4D) while the F1 shows two epi-
topes for CD4+, one epitope for CD8+ T cells (Figure 4C), and
two epitopes for antibodies (Figure 4D).
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FIGURE 1 | Spatial distribution of epitopes in the monomer of
Leishmania donovani nucleoside hydrolase-NH36. (A) Illustration of the
tridimensional surface model of the NH36 tetramer obtained by homology
modeling to the sequence of the nucleoside hydrolase of L. major.
(B) Monomer of L. donovani NH36 with the sequences of the N-terminal
(F1, amino acids 1–103 in lime green), central (F2, amino acids 104–198 in
gray), and C-terminal (F3, amino acids 199–314 in cyan) moieties. (C) MHC
class II-IAd and IEd, haplotype H2d CD4+ T cell epitopes (dark blue), and of
MHC class I Ld-CD8+ T cell predicted epitopes (red) of the C-terminal and
N-terminal moieties. (D) Epitopes for B cells on the C-terminal and
N-terminal moieties (black).
We also studied the immunotherapeutic effect of the NH36,
F1, F2, and F3-saponin vaccines in mice previously infected with
L. amazonensis. On week 6 after infection, when significant dif-
ferences between the sizes of infected and the contra-lateral unin-
fected footpads were already detected, three doses of each vaccine
were injected with weekly intervals. Sera samples were obtained
and analyzed for anti-NH36 antibodies 1 week 9 after complet-
ing vaccination schedule (Figure 2A). Significant variations were
detected for all antibody classes and subtypes (p< 0.0001). The
F3sap vaccine induced levels of anti-NH36 IgA, IgM, IgG, and
IgG2a antibodies as high as the NH36 vaccine and of IgG1 anti-
bodies higher than the F2sap vaccine indicating that the main
NH36 B cell epitopes involved in immunotherapy are located in
the C-terminal moiety of NH36. The F1 vaccine, on the other
hand, induced only IgG2b levels higher than saline controls and
compatible with all other vaccines (Figure 2A).
After immunotherapy, the IDR specific response against L.
amazonensis lysate was predominant in the F3 vaccinated mice,
which showed an IDR as high as the one induced by the NH36
vaccine (Figure 2B). The other peptide vaccines were not different
from the saline treated controls which exhibited, as expected for
CL leishmaniasis, a positive and mild IDR reaction of 0.15 mm at
24 h and 0.06 mm at 48 h (Figure 2B). This result points out the
pre-dominance of the epitopes present at the C-terminal domain
in the generation of a cellular immune response to L. amazonensis
infection.
FIGURE 2 |Therapeutic vaccination, anti-NH36 antibodies, and
intradermal response to L. amazonenis. Six weeks after infection with
105 metacyclic promastigotes of L. amazonensis in the footpads, Balb/c
mice were further vaccinated with three subcutaneous doses of NH36sap,
F1sap, F2sap, or F3sap at weekly intervals. Bars represent the mean±SE
of the absorbance values of anti-NH36 antibodies from 1/100 diluted serum
(A) and intradermal response to the promastigote lysate of L. amazonensis
(24 and 48 h after antigen injection) (B) of two independent experiments
with n=6–7 mice per treatment performed after complete vaccination.
*p<0.05 different from the saline control; ◦p< 0.05 different from the
F2sap vaccine; •from the F1sap vaccine.
As a further measure of the therapeutic effect, we compared
lesion development and parasite burden on week 9 after chal-
lenge. Significant differences between treatments were detected
in the size of the footpad lesions along the time (p< 0.0001).
The NH36sap (p< 0.001), F1sap (p< 0.05), and F3sap vaccines
(p< 0.001) reduced the size of footpad lesions, along the time,
to a similar extent if compared to the untreated infected saline
controls. The F3sap vaccine also showed to be more therapeutic
than the F2sap vaccine (p< 0.05) (not shown). When looking in
detail at the individual footpad sizes on week 9 (Figure 3A), it was
possible to observe that the best therapeutic effect was detected in
the F3sap vaccinated mice, whose mean lesion size (0.23 mm) was
64% (p< 0.001) lower than that of the saline controls (0.64 mm)
and 48% (p< 0.05) lower than that of the F2sap vaccine group
(0.44 mm) (Figure 3A). The sizes of footpad lesions at week 9
were significantly correlated to the number of L. amazonensis
parasites in lesions quantified by RTPCR, which disclosed that
only the N-terminal and C-terminal domains reduced to 82.6%
(p< 0.006) and 81% (p< 0.021), respectively, the number of para-
sites in lesions when compared to the control animals (Figure 3B).
No difference in parasite load was detected between both vaccines
(p< 0.05). Mice treated with F2sap, on the other hand, showed
no decrease in parasite load when compared to the untreated con-
trols (p> 0.05) (Figures 3A,B). None of the animals in the saline
control or F2 vaccine group showed a total absence of parasites,
however, three animals of the F1 and NH36 vaccines, and two
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FIGURE 3 |Therapeutic effect of NH36 vaccines on L. amazonensis
infection. (A) Individual sizes of footpad lesions 9 weeks after infection
with 105 infective promastigotes of L. amazonensis and further treated with
NH36, F1, F2, and F3 vaccines formulated in saponin. Results represent the
mean+SE of the footpad measurements of two independent experiments
(six to seven animals per treatment in each experiment). *p<0.05 different
from the saline control and ◦p<0.05 different from the F2sap vaccine.
(B) Leishmania amazonensis promastigotes in the footpad lesions as
determined by Real Time PCR. *Lines indicate significant differences
compared to the saline control (p<0.05).
animals of the F3 vaccine showed zero parasites in their footpad
lesions.
Furthermore, the cytokine levels secreted to the spleno-
cytes supernatants after stimulation with NH36 were mea-
sured (Figure 4) and significant variations among treatments
were detected for the secretion of IFN-γ (p< 0.001), TNF-α
(p< 0.001), and IL-10 (p< 0.01) (Figures 4A–C). The NH36sap,
F1sap, and F3sap vaccines induced increased levels of IFN-γ
above the saline controls (p< 0.01 for each vaccine) (Figure 4A)
while TNF-α was increased by the F3sap (p< 0.05) and F1sap
(p< 0.05) above the F2sap vaccine (Figure 4B). Additionally, only
the NH36sap (p< 0.01) and F3sap (p< 0.05) vaccines expressed
lower levels of IL-10 than the saline controls (Figure 4C). There-
fore, while the F3 vaccine promoted a TH1 therapeutic response
with high secretion of the pro-inflammatory cytokines IFN-γ
and TNF-α and low levels of the regulatory cytokine IL-10,
the F1 vaccine, differently, induced the increase of IFN-γ and
TNF-α (Figures 4A,B) but no decrease however, of the IL-
10 levels (Figure 4C). The analysis of the IFN-γ/IL-10 ratio
(Figure 4D) disclosed also that the F2sap vaccine did not differ
from the saline control. The higher ratios were seen in ani-
mals treated with the NH36 and F3 vaccines, followed by the
F1sap vaccine (Figure 4D). The TNF-α/IL-10 ratios, on the
other hand were only enhanced by the NH36sap and F3sap vac-
cine above the levels of the saline controls and F2sap vaccine
(Figure 4E).
Based on the requirements of IFN-γ and the roles of TNF-α and
IL-2 as effector cytokines that mediate protection, we assessed the
frequency of NH36-specific IFN-γ, IL-2-, and TNF-α-producing
CD4+ T cells after immunotherapy treatment by multiparameter
cytometry analysis. We initially assessed the total frequencies of
CD4+-T cells producing IFN-γ, IL-2-, and TNF-α, which summa-
rize the frequency of cells that produce each particular cytokine
alone (single producers), and together with one more (double
producers) and two other cytokines (triple cytokines). On week
9 after infection, significant differences between treatments in
the total frequencies of TNF-α (p= 0.0077) and IL-2-producing-
CD4+ T cells of the spleens (p= 0.0035) were found (Figure 5A).
The total frequencies of CD4+ T cells producing TNF-α and IL-2
(Figure 5A) were significantly increased above their saline controls
and reached 35–36%, in the case of F1sap, and 28% in the case of
the F3sap vaccine, while the NH36 vaccine increased only the IL-2-
producing cells to 29%. In agreement with that, the proportion of
CD4+ T cells producing TNF-α+-IL-2+ was increased to 33 and
27%, by the F1sap and F3sap vaccines, respectively (Figure 5B).
On the other hand, the frequencies of IL-2+ and TNF-α single
cytokine producer CD4+ T cells were increased significantly, only
by the F3sap vaccine to 14 and 12%, respectively (Figure 5B).
In contrast to the lack of correlation seen by measuring the total
frequencies of CD4+IFN-γ+ producing cells alone or in combi-
nation with other cytokines (Figures 5A,B), which collectively
developed frequencies below 1%, our analysis showed a high cor-
relation between the frequency of multifunctional (IL-2, TNF-α,
TNF-α-IL-2) CD4+ T cells and the degree of protection. The sizes
of footpad lesions (Figure 3A), which were positively correlated
with the number of parasites (Figure 3B) (R= 0.7239, p< 0.001),
were negatively correlated to the total frequencies of CD4+-
IL-2+ (R=−0.3063; p= 0.0243), CD4+-TNF-α+ (R=−0.2847;
p= 0.0369), CD4+-IL-2+-TNF-α+ (R=−0.2964; p= 0.0295)
and of the CD4+-IL-2+ (R=−0.3611; p= 0.0068) single cytokine
producer T cell populations (Figures 5A,B).
Differences in the quality of the response between vaccine
groups are represented pictorially by pie charts (Figure 5C). Quan-
tifying the fraction of the total cytokine response comprising three
(3+), any two (2+), or any one (1+) cytokine, we found that over
a half of the CD4+-responses in untreated controls, NH36sap and
F3sap vaccines were 1+ cells, while 65% of the response in F1sap
and F2sap vaccines were 2+ cells.
Remarkably, and despite the low global frequency of triple-
cytokine and of IFN-γ producing CD4+ T cells (Figures 5A,B), we
noted a progressive 3,165 and 3,473-fold increase in the median
fluorescence intensity (MFI) for IFN-γ from CD4+ T cells that
secrete all the three cytokines compared with single cytokine-
producing CD4+ T cells (Figure 5D) only in the animals treated
with the F1sap and the F3 vaccines.
On the other hand, the multiparameter analysis of the NH36-
specific CD8+ T cell population, disclosed that the total fre-
quencies of IL-2-producing cells were enhanced to 19, 15, and
20%, respectively, by the NH36, the F1sap, and the F3sap vac-
cines (Figure 6A). The frequency of IL-2+ single cytokine pro-
ducer CD8+ T cells was increased (Figure 6B) above con-
trols and to 10%, by the NH36 vaccine. In correlation with
that, the multifunctional analysis revealed that only the increase
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FIGURE 4 | Cytokine expression. After euthanasia, the secretion of
IFN-γ, TNF-α, and IL-10 were evaluated by an ELISA assay, in the
supernatants of splenocytes, which had been incubated with NH36 for
72 h. Results in (A–C) are presented as means and individual levels of
secreted cytokines, expressed as picogram per milliliter, of two
independent experiments (six to seven mice per treatment in each
experiment) and as the IFN-γ/IL-10 (D) and TNF-α/IL-10 (E) ratios.
*Significant differences between treatments.
FIGURE 5 | Multifunctional analysis discloses the magnitude and
quality of the CD4+ T cell response. NH36-specific cytokine production
from CD4+ T cells of spleens of immunotherapy treated and control mice
9 weeks after infection (A–C). Multiparameter flow cytometry was used to
determine (A) the total frequency of IFN-γ-, IL-2-, or TNF-α-producing CD4+
T cells, (B) the frequency of cells expressing each of the seven possible
combinations of IFN-γ, IL-2, and TNF-α, (C) the magnitude of the IFN-γ
secretion expressed by its median intensity fluorescence (MFI) in single-
and triple-cytokine CD4+ T cell producers and (D) the fraction of the total
response comprising cells expressing all three cytokines (3+), any two
cytokines (2+), or any one cytokine (1+). Results shown as the mean±SE
of two independent experiments with n=6–7 in each experiment.
*Significant differences from saline treated controls, •significant
differences from the F2sap vaccine.
of the CD8+ T cells producing IL-2 or TNF-α or both were
predictive of the therapeutic effect of vaccination. Indeed, the
total frequencies of CD8+-IL-2+ (R=−0.4575; p= 0.004 and
R=−0.4363; p= 0.0292), CD8+-IL-2+-TNF-α+ (R=−0.2795;
p= 0.0407 and R=−0.3820; p= 0.0500) and the CD8+-IL-
2+ single cytokine populations (R=−0.3716; p= 0.0057 and
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FIGURE 6 | Multifunctional analysis discloses the magnitude and
quality of the CD8+ T cell response. NH36-specific cytokine
production from CD8+ T cells of spleens of immunotherapy treated and
control mice 9 weeks after infection (A–C). Multiparameter flow
cytometry was used to determine (A) the total frequency of IFN-γ-,
IL-2-, or TNF-α-producing CD8+ T cells, (B) the frequency of cells
expressing each of the seven possible combinations of IFN-γ, IL-2, and
TNF-α, (C) the magnitude of the IFN-γ secretion expressed by its
median intensity fluorescence (MFI) in single cytokine and
triple-cytokine CD8+ T cell producers and (D) the fraction of the total
response comprising cells expressing all three cytokines (3+), any two
cytokines (2+), or any one cytokine (1+). Results shown as the
mean±SE of two independent experiments with n=6–7 in each
experiment. *Significant differences from saline treated controls.
R=−0.5367; p= 0.0057) were negatively correlated to the sizes of
footpad lesions and the number of parasites in lesions, respectively.
Furthermore, quantifying the fraction of the total cytokine
response of CD8 T cells comprising three (3+), any two (2+),
or any one (1+) cytokine (Figure 6C), we found that while
almost no triple labeled cells were detected in the saline con-
trols (mean= 0.31%), this proportion increased in all vaccinated
groups and exhibited the highest values in the F1sap vaccinated
mice (6.75%). We also found that 72–76% of the response to all
treatments was 1+ cell and from 20 to 32% was 2+ cell. The pro-
portion of the 3+ labeled CD8+ T cells increased therefore at the
expense of the 2+ cell population (Figure 6C).
Regarding the magnitude of the immune response and in
agreement with the highest frequency of triple-producers cells
in F1sap vaccinated mice (Figure 6C), we noted a 1,859-fold
increase in MFI for IFN-γ in CD8+ T cells that secrete all the
three cytokines when compared to the single cytokine-producing
CD8+ T cells (Figure 6D), only in mice treated with the F1sap
vaccine (Figure 6D).
As an alternative method to calculate the magnitude of the
response, the iMFI values were additionally obtained by multiply-
ing the frequency of the single cytokine producer CD4+ T cells and
their MFI of single cytokine producers (Figure 7A). The F3 vaccine
enhanced the iMFI-IL-2 and, together with the NH36 vaccine, also
the iMFI-TNF-α values over the respective saline controls. There
was not any significant variation in the magnitude of the response
(iMFI) of CD8+ T cells for any cytokine by any of the vaccines
(Figure 7B).
Collectively, our multifunctional analysis revealed that
the immunotherapy treatment with NH36 peptide vaccines
determined that the IL-2, TNF-α, and TNF-α-IL-2-CD4+ and
-CD8+ T cells were predictive of protection and immunothera-
peutic potential of the vaccines and that protection improved as
the CD4 responses shifted from 1+ to 2+ and the CD8 responses
shifted qualitatively from 1+ to 3+.
DISCUSSION
Several epitopes for T cell lymphocytes and antibodies where pre-
dicted along the whole sequence of NH36 but they have different
levels of immunogenicity in prophylaxis against L. chagasi infec-
tion (48). The calculation of the surface area of the NH36 model
revealed that the sequences of the F3 and F1 peptides are the most
exposed and this suggests they have a greater availability for lyso-
some or proteaimmunosome enzymes, and hence, the enhanced
probability of being presented by the MHC receptors. The F3 pep-
tide, which has the highest number of predicted epitopes for CD4+
T cells and antibodies (48), has the largest surface area and, is the
target of the strongest cellular and humoral immune response
against L. amazonensis (in this investigation) and L. chagasi (48).
On the other hand, the lower access of the F2 domain to the sur-
face area explains its lower immunogenicity in the L. chagasi (48)
and L. amazonensis infection models, despite the prediction of one
epitope for CD4+, two for CD8+ T cells, and two for antibodies
in its sequence (48).
After immunotherapy of L. amazonensis infection, only the F3
vaccine stands out as the most potent inducer of IgG and IgG2a
anti-NH36 antibodies, while the IgG2b and IgG1 antibodies were
equally enhanced by the F1, F2, and F3 vaccines. Interestingly, the
F1 vaccine was less capable than the F3 vaccine in sustaining the
IgG2a response. Additionally, the F2 vaccine induced an increase
www.frontiersin.org June 2014 | Volume 5 | Article 273 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nico et al. Nucleoside hydrolase domains in cross-therapy
FIGURE 7 |Total functional response of the single cytokine producerT
cells. By multiplying the frequency by the MFI of the single cytokine
producer T cells, we calculated the iMFI that reflects the total functional
response of the population. Single cytokine producer CD4+ (A) and CD8+ T
cells (B). Results shown as the mean±SE of two independent
experiments with n= 6–7 in each experiment. *Significant differences from
saline treated controls.
in IgG1 and IgG2b antibodies, which indicates the advancement of
infection and is not correlated to therapeutic protection. We con-
clude that the most important epitopes for anti-NH36 antibodies
generated after immunotherapy of L. amazonensis or prophylaxis
against L. chagasi infection (48) are located in F3. F3 is then the tar-
get of the anti-Leishmania cross-specific humoral response of mice
(48), and the antibody target of humans and dogs with VL (49)
and of dogs vaccinated with Leishmune® (17). Since the antibodies
generated by the Leishmune® vaccine in dogs reacted mostly with
the F3 epitopes (48) and block the transmission of VL in the insect
vector (18, 19), the identification of these cross-reactive immuno-
genic sequences in F3 might also help in blocking the transmission
of CL.
The IDR to the lysate of L. amazonensis after immunotherapy
was enhanced by the F3 and NH36 vaccines, similarly to what was
detected before and after infection by L. chagasi (48). IDR is a
well known correlate of protection that is expected to be absent
in patients with VL (6) and DCL (7), who show immunosuppres-
sion, but present in cured individuals (6, 7), or after generation
of vaccine protection (16, 17, 48, 54, 55) or in patients with CL
caused by L. braziliensis, which, on the contrary, show a strong
TH1 response (8). In the selection of candidates for clinical trials
of vaccines against CL, IDR is the main criteria for exclusion, as
it indicates sensitization due to previous contact with the para-
site (56). The description of the F3 vaccine and the NH36 vaccine
as good enhancers of the IDR response of mice infected with L.
amazonensis infection is important for the future development of
defined cross-protective vaccines since: (1) L. amazonensis causes
both CL and DCL (2, 7) individuals with DCL are commonly
anergic, showing diminished or absent immune responses to Leish-
mania antigens (3, 7) and (3) the single human vaccine licensed for
immunotherapy of CL leishmaniasis is based on a L. amazonensis
crude vaccine (15).
Additionally, as described for mice prophylaxis against VL and
CL (48) the F3 vaccine was the most therapeutic against L. amazo-
nensis, reducing the size of footpad lesions and the parasite load.
A significant, although different, therapeutic effect was induced
by the F1 vaccine. While both vaccines induced high secretion
of the pro-inflammatory cytokines IFN-γ and TNF-α by spleno-
cytes, only the F3 vaccine exhibited the typical TH1 response with
reduced levels of IL-10. The epitope prediction programs disclosed
the existence of three epitopes for CD4+ in the F3 and two in the
F1 sequences, respectively. The CD8+ T cell epitope prediction
program disclosed the highest affinity for the YPPEFKTKL epi-
tope in F1 and no epitope in F3 (48). Accordingly and as described
for VL (48), an in vivo depletion assay recently demonstrated that,
protection against L. amazonensis infection is mediated by a TH1
CD4+ T cell driven response to F3 and a CD8+ T cell mediated
response to the F1 domain (57).
In agreement with the above mentioned responses, Seder et al.
(51), when describing immune correlates for vaccine-elicited pro-
tection against CL, stated that a CD4+ T-Helper 1-type response is
considered necessary and even sufficient for infection by L. major,
while CD8+ T cells are considered to have an important role in
protection following natural infection and may be important for
optimizing vaccine efficacy. Their model involves the earliest sin-
gle secretion of TNF-α and of IL-2, followed by the development
of double producers (TNF-α and IL-2) and by the later triple-
producers of IFN-γ-TNF-α-IL-2 that can persist as memory or
effector CD4+ T cells. In agreement with that our work revealed
as a correlate of protection, the increase of total frequencies of
TNF-α and IL-2, single and double producers of IL-2-TNF CD4+
T cells while the work of Darrah et al. (52) indicated the triple-
positive CD4+ T cells. This fact could suggest that the MML of L.
major live vaccines promotes a more mature condition of immune
protection. However, while Darrah et al. (52) described the corre-
lation between the triple-cytokine producers and protection only
post-vaccination, our analysis disclosed the correlates after chal-
lenge with L. amazonensis and immunotherapy. Indeed, there is no
description of immune correlates for the protection by the MML
vaccine after challenge with L. major (52). It is worth noting that
it is more difficult to generate protection and disclose the immune
correlates after the establishment of infection than before. Fur-
thermore, while Darrah et al. (52), used cells of draining lymph
nodes of C57BL/6 mice, inoculated with L. major intradermally
in the ear, we used splenocytes of Balb/c mice inoculated with
L. amazonensis in the footpads. Our approach reveals the state of
the systemic cellular immunity. The different antigen and adjuvant
composition of the vaccines could also account for the differences.
In contrast to Darrah et al. (52), we did not find a correlation
between the frequencies of IFN-γ+-producer cells and protection,
and their frequencies were very low. In agreement with Darrah
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et al. (52), however, after immunotherapy with the F3 and F1
vaccines, we observed a progressive increase in the MFI values
of IFN-γ as the degree of functionality increased from single- to
triple-cytokine producers, indicating that IFN-γ might also rep-
resent a contribution to the cellular immune response against L.
amazonensis. Another reason for the detection of low frequencies
of IFN-γ-CD4+ producers by ICS might be the time of in vitro
incubation. After 72 h, the IFN-γ might have already been secreted
and therefore would no longer be inside the cells. The detection of
increased amount of IFN-γ in the supernatants of the same cells,
of mice treated with the NH36, F1, or F3 vaccines confirms that
hypothesis. Furthermore, the time of in vitro incubation might
also be the reason for the higher frequencies of CD4+ (30–40%)
and CD8+ cytokine producers cells (20%). In the work of Darrah
et al. (52), in vitro incubation lasted for 2 h only and the frequencies
of T cells ranged from 0 to 1%.
An important role of the CD8+ T cells in protection against
CL (51, 58) and VL (59) has been reported. Although the NH36
vaccine induced a CD4+ T cell mediated protection or therapy
against VL in mice (43, 47) and dogs (46, 60), the recombinant
NH36-saponin vaccine showed equal contributions of CD4+ and
CD8+ T cells in protection for mice against VL (48) with the F3
being responsible for the CD4+ response toVL (48) and CL and the
F1 being responsible for the main CD8+ T cell driven protection
against L. amazonensis (57).
According to Seder et al. (51), following activation, the naïve
CD8+ T cells fully differentiate into activated effector CD8+ T cells
that secrete IFN-γ, most with cytolytic activity, which can further
differentiate into CD8+ T effect memory cells (TEM) secreting
IFN-γ–TNF-α, either directly, or after a step of conversion, to
CD8+ central memory cells (TCM) which are triple–cytokine pro-
ducers (IFN-γ+-TNF-α+-IL-2+). Therefore, the induction of IL-2
in CD8+ T cells is detected at a later time and is lost in chronic
infections (51). In contrast to CD4+ T cells, it is considered very
rare to find CD8+ TEM cells that produce IL-2. The enhanced abil-
ity of CD8+ TCM cells to produce IL-2 has been shown to confer
improved protection compared with CD8+ TEM cells against a
systemic viral challenge (61). Our results of immunotherapy of L.
amazonensis infection with the F1-saponin vaccine gain relevance
since frequencies of total and single IL-2+ CD8+ T cell produc-
ers were significantly increased, were predictive of the therapeutic
effect and the percentages of triple-cytokine producers were also
increased. We recently demonstrated that protection against L.
amazonensis infection is mediated by the CD8+ T cell response
induced by the F1 vaccine (57). Williams et al. (62) showed the
IL-2 signaling to pathogen-specific CD8+ T cells is required for
the generation of robust secondary responses, programing the
development of CD8+ memory T cells capable of full secondary
expansion. Our results suggest that the F1 domain, which con-
tains the highest affinity epitope of the NH36 for CD8+ T cells
(48), might be important for the development of CD8+ TCM cells
(51), which through the high secretion of IL-2, or TNF or IL-2-
TNF actively contribute to the cure of the established infection.
The intensity of IFN-γ secretion by triple-producers, in our inves-
tigation, also proved to be above the levels of single producers,
indicating the progressive increase in the MFI values of IFN-γ in
F1sap treated mice as the degree of functionality increased.
The F1sap vaccine was also a determinant in the increased secre-
tion of IFN-γ by CD4+ triple-cytokine producers, in the increased
frequencies of total and double TNF-α and IL-2 producers and
in the secretion of IFN-γ and TNF-α into the splenocyte super-
natants indicating the induction of a TH1 response. However,
mice treated with the F1 vaccine also showed a high secretion
of IL-10 by splenocytes. While in VL IL-10 is considered to be
the marker of the severe immunosuppressive disease (5, 63), IL-10
in human CL has been shown to be related to the pathology of
the disease as well as the control of the parasite (64). Recently,
the frequency and functional capacity of Tregs were evaluated in
chronical patients with CL and in asymptomatic subjects (65).
Although, the chronical patients presented higher frequencies of
Tregs in peripheral blood and higher expression of FOXP3 at leish-
manin skin test sites, their CD4+CD25+ cells were less capable
of suppressing antigen specific IFN-γ secretion by effector cells
compared with asymptomatic infected individuals. At the end of
the treatment, both the frequency of CD4+CD25hiCD127− cells
and their capacity to inhibit proliferation and IFN-γ secretion
increased and coincided with healing of CL lesions suggesting that
the restored IL-10 secretion by Tregs was involved in the cure of
the disease (65). The authors suggested that the Tregs impaired
function was evidence of pathogenesis of CL and Treg subsets
would be relevant in designing immunotherapeutic strategies for
recalcitrant dermal leishmaniasis (65). CD4+CD25+ regulatory T
cells have also been shown to restrain pathogenic responses dur-
ing L. amazonensis infection (66). The simultaneous induction of
an immunotherapeutic effect and the increase in the secretion of
IL-10 determined by the F1 peptide might also be related to the
stimulation of Treg subsets and to the presence of epitopes for
Tregs along its sequence.
In our investigation, a significant decrease of IL-10 levels was
found in the supernatants of whole splenocytes of F3 vaccinated
mice. A population of IFNy+-producing CD4+ T cells that also
produce IL-10 has been identified in VL as a feature of T cell differ-
entiation (67). Expanded numbers of these cells were associated
with disease progression (67). Conventional CD11chi DCs that
produce both IL-10 and IL-27 It have also been shown to promote
the production of IL-10 by these effector CD4+ T cells (67). In
our investigation, besides CD4+ T cells, DCs could also be the
source of the IL-10 secretion detected in splenocyte supernatants.
These types of DCs were also present in our mice model of CL
infection. If that is the case, we could assume that immunotherapy
with the F3 peptide formulated with saponin, could promote the
direct shifting of DCs away from an IL-10 producing phenotype,
which is more frequent in the untreated controls, to a pro-Th1
IL-12 producing phenotype, with reduced IL-10 secretion (67).
An alternative source of IL-10, in L. amazonensis infected mice,
could be natural killer (NK) cells. In mice infected with L. dono-
vani, NK cells are found in the spleen and liver hepatic granulomas
(68). They are responsible for suppressing the host resistance to the
parasite, through the secretion of IL-10, which is present in early
infection. In mice with an established infection, the IL-10 mRNA
acquires more stability and IL-10 secretion by NK is enhanced
(68). In the context of CL leishmaniasis, IL-10 has been shown to
be essential for L. major persistence (69). NK cells were also more
frequent in relapsed than in cured cases of mucosal leishmaniasis
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and a decrease in NK cells and in IL-10 levels was observed after
therapy (70).
A few other antigens have been proposed as potential synthetic
vaccines against leishmaniasis (59, 71–73). The kmp-11 protein
of L. donovani has epitopes recognized by human CD8+ lympho-
cytes and by many different HLA receptors (59). The Leish110f
fusion protein of L. major, on the other hand, induced mice
protection mediated by CD4+ lymphocytes (72). Recently, an
adenovirus based vaccine comprising a synthetic HASPB gene
composed of 10 repeats, linked to the KMP-11 gene, was obtained
and assayed in the therapy of L. donovani infected mice ther-
apeutics (73). The synthetic gene was cloned using humanized
codons. The immunogenicity increased if the vaccine was admin-
istered in the footpads instead of subcutaneously. A detailed study
of the contribution of the epitopes of HASPB protein was per-
formed. After therapeutic vaccination, the IgG1 and IgG2a anti-
body responses were enhanced and IFN-γ-CD8+ T cell response,
mainly to HASPB, became apparent. Interestingly, a single dose of
the vaccine reduced the parasite growth in spleens by 66% (73).
Immunotherapy for the treatment of human VL leishmani-
asis has recently been recommended (74). The C-terminal and
N-terminal domains of NH36 of L. donovani are the basis of
the strong immunotherapeutic effect against L. amazonenis infec-
tion. Our findings contribute to the design of defined vaccines for
cross-protection against CL leishmaniasis.
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